These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21861540)

  • 1. Management of recurrent head and neck cancer: recent progress and future directions.
    Brockstein BE
    Drugs; 2011 Aug; 71(12):1551-9. PubMed ID: 21861540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
    Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
    BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment options for metastatic head and neck cancer.
    Price KA; Cohen EE
    Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
    Frampton JE
    Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
    Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB
    Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Mesía R; Rivera F; Kawecki A; Rottey S; Hitt R; Kienzer H; Cupissol D; De Raucourt D; Benasso M; Koralewski P; Delord JP; Bokemeyer C; Curran D; Gross A; Vermorken JB
    Ann Oncol; 2010 Oct; 21(10):1967-1973. PubMed ID: 20335368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
    Péron J; Polivka V; Chabaud S; Poupart M; Ceruse P; Ramade A; Girodet D; Zrounba P; Fayette J
    BMC Cancer; 2014 Jul; 14():504. PubMed ID: 25011678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
    Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
    N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Khuri FR
    Head Neck; 2013 Mar; 35(3):443-53. PubMed ID: 22052826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.
    Bagust A; Greenhalgh J; Boland A; Fleeman N; McLeod C; Dickson R; Dundar Y; Proudlove C; Shaw R
    Pharmacoeconomics; 2010; 28(6):439-48. PubMed ID: 20465313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
    Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
    Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.
    Mesía R; Palmero R; Cos M; Vilajosana E; Vázquez S
    Head Neck Oncol; 2010 Jan; 2():3. PubMed ID: 20181021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
    Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
    Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
    Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
    Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.